What's Hot
View all perspectives
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abst 1515
Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA
- CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue
- 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased
#ACR21 @RheumNow https://t.co/TWLym8oHuK
swethaann23 swethaann23
3 years 1 month ago
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years
⭐️No statistical difference pneumonia trend in PsA
Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
Dr. John Cush RheumNow
3 years 1 month ago
We are live!
RheumNow Daily Recap - #ACR21 https://t.co/ILaj7CImXY via @YouTube
Dr. John Cush RheumNow
3 years 1 month ago
Rheumatologists and Healthcare Professionals: Join us tonight for RheumNow's #ACR21 Rheumatology Roundup at 7pm Eastern time - broadcast live on our YouTube Channel. Search RheumNow on YouTube.
https://t.co/dXNzeGFEds https://t.co/TJ7BEuLKsa
swethaann23 swethaann23
3 years 1 month ago
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC).
Mean times to PsA diagnosis
66d ▶️ DA
77d ▶️SOC
Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 swethaann23
3 years 1 month ago
⭐️Prevalent drug utilization was not related to enthesitis activity
⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i
⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx
Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
Dr. John Cush RheumNow
3 years 1 month ago
What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting.
https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
3 years 1 month ago
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.
https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abst 1517
Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE
- Most common rheumatic IRAE = inflammatory arthritis
- Higher prevalence of ANA in those tx w/ chemo prior to ICI
#ACR21 @RheumNow https://t.co/7qgogSMjUr
David Liew drdavidliew
3 years 1 month ago
Put those two RF together (essentially nailing down RA pts at risk of cancer):
age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30)
age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24)
neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55)
#ACR21 @RheumNow https://t.co/Uvr4wBhFVF
David Liew drdavidliew
3 years 1 month ago
So I guess you can look at this as you want:
Arguably, if you are <65 & a never smoker, then maybe the risk isn't there.
Once you start adding risk - maybe this is something we need to be having hard conversations with pts about.
Plenty to think about here...
#ACR21 @RheumNow
David Liew drdavidliew
3 years 1 month ago
There will be plenty of debate about ORAL Surveillance, as there should be.
We will see more granular data, as we should.
Whatever the case, it's hard to argue that there's no cancer risk with tofacitinib vs TNFi in RA, at least for some patients at higher risk.
#ACR21 @RheumNow
Poster Hall